Q4 2024 Earnings Call Transcript February 13, 2025 DexCom, Inc. misses on earnings expectations. Reported EPS is $0.45 EPS, expectations were $0.4792. Operator: Thank you for standing by. My name is ...
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an ...
Dexcom, Inc.'s (NASDAQ:DXCM) fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus ...
Stratos Wealth Partners LTD. purchased a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the fourth quarter, HoldingsChannel.com reports. The fund purchased 2,583 shares of the medical device ...
Hosted on MSN16h
Dexcom Stock Makes A Recovery After Its Fourth-Quarter FumbleDexcom stock stock recovered Friday after the diabetes devices maker missed fourth-quarter profit expectations.
Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...
JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 ...
2-Year U.S. Treasury Note Continuous Contract $102.750 0.086 0.08% 5-Year U.S. Treasury Note Continuous Contract $106.500 0.234 0.22% 10-Year U.S. Treasury Note Continuous Contract $109.297 0.328 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback